Sage Journals: Discover world-class research

Abstract

Background

Adiponectin is viewed as an insulin-sensitizing hormone with anti-inflammatory effects. In accordance, plasma adiponectin is decreased in metabolic disorders including type 2 diabetes mellitus (T2DM). However, in spite of the apparently beneficially effects, recent data from large prospective studies have consistently linked high adiponectin levels with increased cardiovascular (CV) disease and mortality, thus questioning the positive view on adiponectin. Accordingly, we investigated the relationship between adiponectin, incident T2DM and subsequently CV events.

Methods

We prospectively followed 5349 randomly selected men and women from the community, without T2DM or CV disease. Plasma adiponectin was measured at study entry. Median follow-up time was 8.5 years (IQR 8.0–9.1 years). During follow up, 136 participants developed T2DM. Following their diagnosis, 36 of the 136 participants experienced a CV event (myocardial infarction, ischaemic stroke, or CV death).

Results

Participants with increasing adiponectin had reduced risk of developing T2DM (p < 0.001). After adjustment for confounding risk factors (including age, gender, body mass index, physical activity, alcohol consumption, blood glucose, HbA1c, blood pressure, lipids, high-sensitivity C-reactive protein, estimated glomerular filtration rate, and plasma N-terminal pro-brain natriuretic peptide, competing risk Cox-regression analysis identified adiponectin as an independent predictor of T2DM: hazard ratio (HR) for each doubling of adiponectin 0.55 (95% CI 0.41–0.74; p < 0.001). After development of T2DM, the risk of a CV event more than doubled. Increasing adiponectin (adjusted for the confounding risk factors mentioned) was associated with reduced risk of CV events: HR 0.34 (95% CI 0.16–0.72; p = 0.005) for each doubling in plasma adiponectin.

Conclusions

In conclusion, increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.

Keywords

Adiponectin cardiovascular disease type 2 diabetes T2DM

Get full access to this article

View all access options for this article.

References

Kadowaki

Yamauchi

Kubota

. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784–1792.

Saltevo

Laakso

Jokelainen

. Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population-based study. Diabetes Metab Res Rev 2008; 24: 378–383.

Koenig

Khuseyinova

Baumert

. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006; 48: 1369–1377.

Wannamethee

Lowe

Rumley

. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007; 30: 1200–1205.

Heidemann

Sun

van Dam

. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008; 149: 307–316.

Ley

Harris

Connelly

. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 2008; 31: 1410–1415.

Tabak

Brunner

Miller

. Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 2009; 41: 626–629.

Schnabel

Messow

Lubos

. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 2008; 29: 649–657.

Tsukamoto

Fujita

Kato

. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009; 53: 2070–2077.

10.

Wannamethee

Welsh

Whincup

. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovasc Prev Rehabi 2011; 18: 65–71.

11.

Fine

Gray

. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Ass 1999; 94: 496–509.

12.

Mogelvang

Goetze

Schnohr

. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol 2007; 50: 1694–1701.

13.

Madsen

Davidsen

Rasmussen

. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 124–130.

14.

Lindberg

Mogelvang

Pedersen

. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol 2013; 111: 1139–1145.

15.

Goetze

Kastrup

Pedersen

. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002; 48: 1035–1042.

16.

Stevens

Coresh

Greene

. Assessing kidney function–measured and estimated glomerular filtration rate. N Eng J Med 2006; 354: 2473–2483.

17.

Tabak

Carstensen

Witte

. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care 2012; 35: 2540–2547.

18.

Rabe

Lehrke

Parhofer

. Adipokines and insulin resistance. Mol Med 2008; 14: 741–751.

19.

Lee

Magkos

Mantzoros

. Effects of leptin and adiponectin on pancreatic beta-cell function. Metabolism 2011; 60: 1664–1672.

20.

Tsuchida

Yamauchi

Ito

. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 30817–30822.

21.

Mather

Funahashi

Matsuzawa

. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57: 980–986.

22.

Hanley

Wagenknecht

Norris

. Adiponectin and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. Diabetes Care 2011; 34: 2231–2236.

23.

Di Angelantonio

Chowdhury

Sarwar

. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177–2187.

24.

Magnusson

Jujic

Hedblad

. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab 2012; 97: 638–645.

25.

Swellam

Sayed

Abdel-Fatah Ali

. Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus. Dis Mark 2009; 27: 269–278.

26.

Berg

Combs

. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947–953.

27.

Zhao

Wen

. Changes in serum adiponectin concentrations and endothelial function after intensive insulin treatment in people with newly diagnosed type 2 diabetes: a pilot study. Diab Res Clin Pract 2011; 94: 186–192.

28.

Rasouli

Kern

. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S64–S73.

29.

Kizer

Arnold

Benkeser

. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 2012; 35: 415–423.

Adiponectin,type 2 diabetes and cardiovascular risk